Table 3.
The relationship between SCCA, NSE, CEA, and CYFRA21-1 and the clinicopathological factors (ng/mL, ).
| Clinicopathological characteristics | N | SCCA | NSE | CEA | CYFRA21-1 |
|---|---|---|---|---|---|
| Histological classification | |||||
| Adenocarcinoma | 68 | 0.22 ± 0.26 | 17.95 ± 8.30 | 30.76 ± 46.78* | 4.00 ± 3.76 |
| Squamous cell lung cancer | 56 | 3.79 ± 5.56* | 16.83 ± 5.66 | 4.49 ± 2.49 | 10.34 ± 9.38* |
| Small cell lung cancer | 8 | 0.15 ± 0.07 | 50.80 ± 22.60* | 1.81 ± 1.05 | 1.31 ± 0.30 |
| NSCLC TNM stage | |||||
| I/II | 73 | 2.59 ± 4.92 | 15.21 ± 4.53 | 7.44 ± 8.36 | 7.32 ± 9.01 |
| III/IV | 51 | 0.70 ± 1.03 | 21.94 ± 19.15 | 33.71 ± 50.04* | 5.65 ± 3.99 |
| SCLC stage | |||||
| Limited disease (LD) | 3 | 2.06 ± 1.87 | 23.43 ± 16.74 | 7.27 ± 6.12 | 7.11 ± 5.23 |
| Extensive disease (ED) | 5 | 0.86 ± 0.79 | 25.02 ± 10.90 | 33.51 ± 29.63* | 5.92 ± 3.80 |
P value was calculated by Student's t-test *P < 0.05.